Whilst we are all keen to get in on the potential cure experiment front for covid-19, I ask the question. Is there a risk of rushing in trying to provide a treatment to a patient perhaps unfortunately on death's door and a unsuccessful outcome taints our otherwise impressive product? Not because of the treatment, but the circumstances related to the patient health prior. Will that be the thing that gets remember more than the effort? Or of course on the other hand a successful outcome would make world headlines!
Risks worth considering?
Cynata has manufacturing solution for new covd treatments, page-38
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.20M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $5.809K | 29.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48825 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.21pm 07/08/2024 (20 minute delay) ? |
| CYP (ASX) Chart |